Perspective Open Access
Like 0


Individuals with latent tuberculosis infection (LTBI) are the reservoir of in a population and as long as this reservoir exists, elimination of tuberculosis (TB) will not be feasible. In 2013, the European Centre for Disease Prevention and Control (ECDC) started an assessment of benefits and risks of introducing programmatic LTBI control, with the aim of providing guidance on how to incorporate LTBI control into national TB strategies in European Union/European Economic Area (EU/EEA) Member States and candidate countries. In a first step, experts from the Member States, candidate countries, and international and national organisations were consulted on the components of programmatic LTBI control that should be considered and evaluated in literature reviews, mathematical models and cost-effectiveness studies. This was done through a questionnaire and two interactive discussion rounds. The main components identified were identification and targeting of risk groups, determinants of LTBI and progression to active TB, optimal diagnostic tests for LTBI, effective preventive treatment regimens, and to explore the potential for combining LTBI control with other health programmes. Political commitment, a solid healthcare infrastructure, and favourable economic situation in specific countries were identified as essential to facilitate the implementation of programmatic LTBI control.


Article metrics loading...

Loading full text...

Full text loading...



  1. European Centre for Disease Prevention and Control (ECDC)/World Health Organization Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2015. Stockholm: ECDC; 2015. Available from: http://ecdc.europa.eu/en/publications/Publications/tuberculosis-surveillance-monitoring-Europe-2015.pdf
  2. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol. 2009;17(5):183-8.  https://doi.org/10.1016/j.tim.2009.02.005  PMID: 19375916 
  3. Lönnroth K, Migliori GB, Abubakar I, D’Ambrosio L, de Vries G, Diel R, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45(4):928-52. PMID: 25792630 
  4. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC, WHO Global Surveillance and Monitoring Project. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA. 1999;282(7):677-86.  https://doi.org/10.1001/jama.282.7.677  PMID: 10517722 
  5. Capocci S, Smith C, Morris S, Bhagani S, Cropley I, Abubakar I, et al. Decreasing cost effectiveness of testing for latent TB in HIV in a low TB incidence area. Eur Respir J. 2015;46(1):165-74.  https://doi.org/10.1183/09031936.00067114  PMID: 25882810 
  6. Erkens CG, Slump E, Verhagen M, Schimmel H, de Vries G, Cobelens F, et al. Monitoring latent tuberculosis infection diagnosis and management in the Netherlands. Eur Respir J. 2016;47(5):1492-501.  https://doi.org/10.1183/13993003.01397-2015  PMID: 26917614 
  7. Muller G. Idea-Factory method. Utrecht: Hepta Aps. [Accessed: 6 December 2013]. Available from: http://www.idea-factory.org/
  8. Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46(6):1563-76.  https://doi.org/10.1183/13993003.01245-2015  PMID: 26405286 
  9. Stuurman AL, Vonk Noordegraaf-Schouten M, van Kessel F, Oordt-Speets AM, Sandgren A, van der Werf MJ. Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review. BMC Infect Dis. 2016;16(1):257.
  10. Sandgren A, Vonk Noordegraaf-Schouten M, van Kessel F, Stuurman A, Oordt-Speets A, van der Werf MJ. Initiation and completion rates for latent tuberculosis infection treatment: a systematic review. BMC Infect Dis. 2016;16(1):204.
  11. Stagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014;161(6):419-28.
  12. den Boon S, Matteelli A, Getahun H. Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016;20(8):1065-71.
  13. Sotgiu G, Matteelli A, Getahun H, Girardi E, Sañé Schepisi M, Centis R, et al. Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. Eur Respir J. 2015;45(4):1170-3.
  14. Den Boon S, Matteelli A, Ford N, Getahun H. Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV. AIDS. 2016;30(5):797-801.
Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error